MARKET

IKT

IKT

Inhibikase Therapeutics Inc
NASDAQ
1.700
-0.090
-5.03%
After Hours: 1.700 0 0.00% 17:17 04/16 EDT
OPEN
1.790
PREV CLOSE
1.790
HIGH
1.790
LOW
1.670
VOLUME
841.20K
TURNOVER
--
52 WEEK HIGH
2.365
52 WEEK LOW
1.330
MARKET CAP
224.46M
P/E (TTM)
-3.4630
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at IKT last week (0406-0410)?
Weekly Report · 3d ago
Buy Rating on IKT-001: De-Risked Late-Stage PAH Program with Adaptive Phase 3 Design and Solid Financial Runway
TipRanks · 04/08 18:55
Inhibikase Therapeutics: Phase 3 IKT-001 PAH Program and De-Risked Imatinib-Based Efficacy Drive Buy Rating and $8 Target
TipRanks · 04/08 10:16
Inhibikase Begins Pivotal Phase 3 Trial in PAH
TipRanks · 04/07 12:54
Inhibikase Therapeutics enrolls first patient in IMPROVE-PAH study
TipRanks · 04/07 12:42
Inhibikase enrolls first patient in Phase 3 IMPROVE-PAH trial for IKT-001
Reuters · 04/07 12:06
Inhibikase Therapeutics Says First Patient Enrolled In Pivotal Phase 3 Study IMPROVE-PAH For Treatment Of Pulmonary Arterial Hypertension
Benzinga · 04/07 12:03
INHIBIKASE THERAPEUTICS ANNOUNCES ENROLLMENT OF FIRST PATIENT IN IMPROVE-PAH GLOBAL PHASE 3 STUDY OF IKT-001 IN THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION
Reuters · 04/07 12:00
More
About IKT
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary disease. The Company’s multi-therapeutic pipeline includes IKT-001, a prodrug of imatinib mesylate, for pulmonary arterial hypertension (PAH).

Webull offers Inhibikase Therapeutics Inc stock information, including NASDAQ: IKT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IKT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IKT stock methods without spending real money on the virtual paper trading platform.